Pure Global
NCT06108349

Topical Cannabidiol for Treating Carpal Tunnel Syndrome

A Randomized Controlled Trial of Topical Cannabidiol for the Treatment of Carpal Tunnel Syndrome
University of Virginia·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Carpal Tunnel Syndrome
Drug/Device/Intervention
Cannabidiol
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
University of Virginia
Timeline & enrollment
Phase
Phase 2
Start date
Nov 01, 2023
End date
Dec 01, 2024
Enrollment
20 participants
Primary outcome

Feasibility of CBD as a topical treatment for CTS is determined by the investigator by evaluating the Recruitment Rate, medication compliance rate and retention rate.

Summary

The Purpose of this study is to assess the safety and efficacy of Cannabidiol on treatment of
 Carpal Tunnel Syndrome.

ICD-10 classifications
Carpal tunnel syndromeTarsal tunnel syndromeArthrosis of first carpometacarpal joint, unspecifiedArthrosis of first carpometacarpal jointOther specified disorders of synovium and tendon
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06108349
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06108349 through Pure Global AI's free database. This Phase 2 trial is sponsored by University of Virginia and is currently Not yet recruiting. The study focuses on Carpal Tunnel Syndrome. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.